Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis

Immunotherapy

Volumn 7, Issue 9, 2015, Pages 1023-1037

  Chen, Yan ^a,b   Qian, Tian ^a   Zhang, Dongmei ^a   Yan, Heng ^a   Hao, Fei ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b KUNMING GENERAL HOSPITAL   (China)

Author keywords

anti IL 17 agents; brodalumab; efficacy; ixekizumab; meta analysis; psoriasis; safety; secukinumab

Indexed keywords

ANTIPSORIASIS AGENT; BRODALUMAB; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; IXEKIZUMAB; SECUKINUMAB; MONOCLONAL ANTIBODY;

BIOLOGICAL THERAPY; DRUG EFFICACY; DRUG SAFETY; ECTOPIC PREGNANCY; HUMAN; KIDNEY COLIC; MELANOMA; NEUTROPENIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; META ANALYSIS; NASOPHARYNGITIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; NASOPHARYNGITIS; PSORIASIS; TREATMENT OUTCOME;

EID: 84945472756     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.50     Document Type: Review

References (30)

1. Chamoun A, Goudetsidis L, Poot F, Bourdeaud'hui F, Titeca G. Psoriasis and depression. Rev. Med. Brux. 36(1), 23-28 (2015).
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 370(9583), 263-271 (2007).
3. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J. Am. Acad. Dermatol. 60(2), 218-224 (2009).
4. Sobell JM, Leonardi CL. Therapeutic development in psoriasis. Semin. Cutan. Med. Surg. 33(4 Suppl.), S69-S72 (2014).
5. Gottlieb AB, Cooper KD, McCormick TS et al. A Phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23(5), 1081-1092 (2007).
6. Ramirez-Carrozzi V, Sambandam A, Luis E et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12(12), 1159-1166 (2011).
7. Lopes LC, Silveira MS, Camargo IA et al. Biological drugs for the treatment of psoriasis in a public health system. Rev. Saude Publica 48(4), 651-661; discussion 661 (2014).
8. Cordiali-Fei P, Bianchi L, Bonifati C et al. Immunologic biomarkers for clinical and therapeutic management of psoriasis. Mediators Inflamm. 2014, 236060 (2014).
9. Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: The science behind the scenes. J. Invest. Dermatol. 135(1), 31-38 (2015).
10. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin. Invest. Drugs 22(8), 993-1005 (2013).
11. Wu JJ. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. N. Engl. J. Med. 367(3), 274-275; author reply 275 (2012).
12. Brown G, Malakouti M, Wang E, Koo JY, Levin E. Anti-IL-17 Phase II data for psoriasis: A review. J. Dermatol. Treat. 26(1), 32-36 (2015).
13. ClinicalTrials.gov. www.clinicaltrials.gov
14. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52ra72 (2010).
15. Papp KA, Reid C, Foley P et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a Phase I, randomized, placebo-controlled trial. J. Invest. Dermatol. 132(10), 2466-2469 (2012).
16. Leonardi C, Matheson R, Zachariae C et al. Antiinterleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190-1199 (2012).
17. Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderateto-severe plaque psoriasis: A randomized, double-blind, placebo-controlled Phase II dose-ranging study. Br. J. Dermatol. 168(2), 412-421 (2013).
18. Krueger JG, Fretzin S, Suárez-Fariñas M et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol. 130(1), 145-154.e9 (2012).
19. Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-tosevere plaque psoriasis: A randomized, double-blind, placebo-controlled, Phase II regimen-finding study. Br. J. Dermatol. 168(2), 402-411 (2013).
20. Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181-1189 (2012).
21. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis-results of two Phase 3 trials. N. Engl. J. Med. 371(4), 326-338 (2014).
22. Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J. Eur. Acad. Dermatol. Venereol. 28(7), 846-852 (2014).
23. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: A unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 141(2), 133-142 (2014).
24. Gordon KB, Kimball AB, Chau D et al. Impact of brodalumab treatment on psoriasis symptoms and healthrelated quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br. J. Dermatol. 170(3), 705-715 (2014).
25. McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, Phase II proof-of-concept trial. Ann. Rheum. Dis. 73(2), 349-356 (2014).
26. Gordon KB, Leonardi CL, Lebwohl M et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 71(6), 1176-1182 (2014).
27. Ratner M. IL-17-targeting biologics aim to become standard of care in psoriasis. Nat. Biotechnol. 33(1), 3-4 (2015).
28. Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J. Cutan. Med. Surg. 19(2), 109-114 (2015).
29. Kyriakou A, Patsatsi A, Vyzantiadis TA, Sotiriadis D. Serum Levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J. Immunol. Res. 2014, 467541 (2014).
30. Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 26(1), 25-33 (2015).